Onward Medical N.V./€ONWD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Onward Medical N.V.
ONWARD Medical N.V. is a medical technology company specializing in spinal cord stimulation therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries (SCI) and other movement disabilities. Founded in 2014 by researchers at the Swiss Federal Institute of Technology (EPFL), the company is headquartered in Eindhoven, the Netherlands, with additional offices in Lausanne, Switzerland, and Boston, Massachusetts. Its product portfolio includes the ARC-EX System, a non-invasive device designed to enhance upper limb function, and the investigational ARC-IM System, an implantable solution targeting blood pressure stability and other SCI-related symptoms. In 2024, ONWARD Medical secured exclusive rights to develop and commercialize the WIMAGINE Brain-Computer Interface (BCI), positioning the company to integrate thought-driven movement capabilities into its therapies. The company has also received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA) for its innovative approaches to SCI treatment.
- Ticker
- €ONWD
- Sector
- Health
- Primary listing
- BSE
- Employees
- 137
- Headquarters
- Eindhoven, Netherlands
- Website
- www.onwd.com
ONWD Metrics
BasicAdvanced
€123M
-
-€0.85
0.85
-
Price and volume
Market cap
€123M
Beta
0.85
52-week high
€4.80
52-week low
€1.73
Average daily volume
191K
Financial strength
Current ratio
9.226
Quick ratio
8.604
Long term debt to equity
0.188
Total debt to equity
0.192
Interest coverage (TTM)
-20.33%
Profitability
EBITDA (TTM)
-43.463
Gross margin (TTM)
75.36%
Net profit margin (TTM)
-537.60%
Operating margin (TTM)
-525.44%
Effective tax rate (TTM)
-0.99%
Revenue per employee (TTM)
€60,000
Management effectiveness
Return on assets (TTM)
-35.30%
Return on equity (TTM)
-90.85%
Valuation
Price to revenue (TTM)
11.289
Price to book
1.71
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-2.041
Free cash flow yield (TTM)
-49.00%
Free cash flow per share (TTM)
-0.869
Growth
Revenue change (TTM)
210.05%
Earnings per share change (TTM)
9.23%
3-year revenue growth (CAGR)
58.55%
3-year earnings per share growth (CAGR)
-10.84%
What the Analysts think about ONWD
Analyst ratings (Buy, Hold, Sell) for Onward Medical N.V. stock.
Analyst projections of the future price of Onward Medical N.V. stock.
ONWD Financial Performance
Revenues and expenses
ONWD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.